Original Publication Date: 18 March, 2015
Publication / Source: Future Oncology
Authors: Jeanny B Aragon-Ching
Androgen deprivation therapy (ADT) has been the cornerstone of treatment for metastatic prostate cancer. Since the emergence of castration resistance, attempts to define mechanisms of resistance has led the field into a search for nonandrogen receptor (AR)-driven targets. This brought on an era of investigation that began with the use of chemotherapy for prostate cancer. While chemotherapy has been one of the earliest established treatments for men with symptomatic prostate cancer, based on the TAX327 and SWOG 9916 trials, it has only recently been established that the role of chemotherapy may not be limited to microtubule inhibition alone, but also inhibition of AR nuclear translocation [1,2].